LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

Benzinga · 2d ago
LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.